New hope for calming Alzheimer's agitation
Symptom relief
Recruiting now
This study is testing two new drugs, EXV-802 and EXV-801, to see if they can safely reduce agitation in people with Alzheimer's dementia. About 300 participants, aged 55-90, will be randomly assigned to receive one of the drugs or a placebo for 6 weeks. The main goal is to see if…
Phase: PHASE2, PHASE3 • Sponsor: Exciva GmbH • Aim: Symptom relief
Last updated Mar 23, 2026 15:16 UTC